Jean Bergeron is a physician acting as consultant and clinical scientist at the, Endocrinology and Nephrology Research Unit, Centre de recherche du CHU de Québec – Université Laval, as well as Professor at the Molecular Biology, Medical Biochimistry and Pathology Department, Faculty of Medicine, Laval University. He is member of the Medical Biochimistry Unit (Department of Laboratory Medicine) and chief of the Lipid clinic (Department of Medicine) of the CHU de Québec-Université Laval. He is also Secretary for the Société Québécoise de Lipidologie, Nutrition et Métabolisme (SQLNM), a scientific society from which he received in 2012 a recognition award, Le prix des Fondateurs Jean Davignon et Paul-J. Lupien, for his outstanding contribution in the field of lipidology. As specialist in laboratory medicine and lipidology, he supervises the CHU de Québec – Laval University clinical lipid laboratory performing lipoprotein, lipid and gene analyses.

 

Interest in clinical research

During his career, he has been dedicated to a better understanding of clinical and biological expressions of primary and secondary hyperlipidemia. He has also participated in the development and application of up to date lipid guidelines for clinicians and contributed to the characterization of new metabolic markers related to atherosclerosis and heart disease. He participated to numerous clinical trials using statins and new emergent therapies in lipoprotein metabolism.

 

Actual clinical research

More recently, he is involved in research on statin-generated myopathy, including identification of blood or genetic markers related to statin side effect and development of clinical tools for a better support to patients suffering from this condition. He is involved in the Canadian Familial Hypercholesterolemia registry. Finally, he is principal investigator in several clinical trials using PCSK9 inhibitors, anti-sense oligonucleotides, ANGPTL-3 inhibitors, and in some cases, gene therapy for very severe hypercholesterolemia or patients at very high CV risk for premature atherosclerotic heart disease.

 

CHUL
2705, boulevard Laurier
C-00-224
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

81 entries « 1 of 9 »

Hogue JC, Lamarche B, Gaudet D, Larivière M, Tremblay AJ, Bergeron J, Lemieux I, Després JP, Gagné C, Couture P

Relationship between cholesteryl ester transfer protein and LDL heterogeneity in familial hypercholesterolemia.

Journal Article

J Lipid Res, 45 (6), pp. 1077-83, 2004, ISSN: 0022-2275.

Abstract | Links:

Tremblay AJ, Lamarche B, Ruel IL, Hogue JC, Bergeron J, Gagné C, Couture P

Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation.

Journal Article

J Lipid Res, 45 (5), pp. 866-72, 2004, ISSN: 0022-2275.

Abstract | Links:

Tremblay AJ, Després JP, Piché ME, Nadeau A, Bergeron J, Alméras N, Tremblay A, Lemieux S

Associations between the fatty acid content of triglyceride, visceral adipose tissue accumulation, and components of the insulin resistance syndrome.

Journal Article

Metabolism, 53 (3), pp. 310-7, 2004, ISSN: 0026-0495.

Abstract | Links:

Piché ME, Després JP, Pascot A, Nadeau A, Tremblay A, Weisnagel SJ, Bergeron J, Lemieux S

Predictors of the development of impaired fasting glucose versus impaired glucose tolerance are partly different in men: a 6-year follow-up study.

Journal Article

Diabetologia, 47 (3), pp. 590-2, 2004, ISSN: 0012-186X.

| Links:

Tremblay AJ, Lamarche B, Ruel I, Hogue JC, Bergeron J, Gagné C, Couture P

Lack of evidence for reduced plasma apo B48 catabolism in patients with heterozygous familial hypercholesterolemia carrying the same null LDL receptor gene mutation.

Journal Article

Atherosclerosis, 172 (2), pp. 367-73, 2004, ISSN: 0021-9150.

Abstract | Links:

Couillard C, Bergeron J, Després JP, Gagnon J, Rankinen T, Leon AS, Rao DC, Skinner JS, Wilmore JH, Bouchard C

Apolipoprotein AI- and AI:AII-containing lipoproteins in white men and women of the HERITAGE Family study: Associations with metabolic risk profile variables.

Journal Article

Metabolism, 52 (12), pp. 1530-6, 2003, ISSN: 0026-0495.

Abstract | Links:

Desmeules A, Couillard C, Tchernof A, Bergeron J, Rankinen T, Leon AS, Rao DC, Skinner JS, Wilmore JH, Després JP, Bouchard C

Post-heparin lipolytic enzyme activities, sex hormones and sex hormone-binding globulin (SHBG) in men and women: The HERITAGE Family Study.

Journal Article

Atherosclerosis, 171 (2), pp. 343-50, 2003, ISSN: 0021-9150.

Abstract | Links:

Blackburn P, Lamarche B, Couillard C, Pascot A, Bergeron N, Prud'Homme D, Tremblay A, Bergeron J, Lemieux I, Després JP

Postprandial hyperlipidemia: another correlate of the 'hypertriglyceridemic waist' phenotype in men.

Journal Article

Atherosclerosis, 171 (2), pp. 327-36, 2003, ISSN: 0021-9150.

Abstract | Links:

Blackburn P, Lamarche B, Couillard C, Pascot A, Tremblay A, Bergeron J, Lemieux I, Després JP

Contribution of visceral adiposity to the exaggerated postprandial lipemia of men with impaired glucose tolerance.

Journal Article

Diabetes Care, 26 (12), pp. 3303-9, 2003, ISSN: 0149-5992.

Abstract | Links:

Couture P, Archer WR, Lamarche B, Landry N, Dériaz O, Corneau L, Bergeron J, Bergeron N

Influences of apolipoprotein E polymorphism on the response of plasma lipids to the ad libitum consumption of a high-carbohydrate diet compared with a high-monounsaturated fatty acid diet.

Journal Article

Metabolism, 52 (11), pp. 1454-9, 2003, ISSN: 0026-0495.

Abstract | Links:

81 entries « 1 of 9 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
Data provided by the Université Laval research projects registery